Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 9/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.61 |
| ▸ | F2 | P00734 | 3/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.58 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL15485473 | 0.95 | PRSS1 (0.57) | PRSS1ITGB3ITGA2BF2PRSS2 | |
| SCHEMBL7148427 | 0.87 | PRSS1 (0.61) | PRSS1ITGB3ITGA2BF2PRSS2 | |
| SCHEMBL8639589 | 0.85 | L3MBTL1 (0.46) | PRSS1ITGB3ITGA2B | |
| SCHEMBL5692310 | 0.82 | ALDH1A1 (0.44) | — | |
| SCHEMBL2524064 | 0.81 | ITGB3 (0.43) | PRSS1ITGB3ITGA2BF2PRSS2 | |
| SCHEMBL11647073 | 0.80 | CA1 (0.41) | PRSS1ITGB3ITGA2B | |
| SCHEMBL400499 | 0.80 | TP53 (0.52) | — | |
| SCHEMBL29051542 | 0.80 | ALDH1A1 (0.46) | ITGB3ITGA2B | |
| SCHEMBL6370923 | 0.80 | ITGB3 (0.43) | PRSS1ITGB3ITGA2BF2PRSS2 | |
| SCHEMBL4426386 | 0.80 | F7 (0.64) | PRSS1ITGB3ITGA2BF2PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | claimed |
| US-6649593-B1 | Amino acid derivatives including serine, leucine, valine, arginine, asparginine, methionine, glycine and phenylalanine units; S1 protease inhibition; modulation of cholesterol homeostasis in cells | TULARIK INC. | 2003-11-18 | — | — | US | claimed |
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | claimed |
| JP-2002506075-A | — | — | 2002-02-26 | — | — | JP | claimed |
| WO-2001027138-A2 | MODULATORS OF SREBP PROCESSING | TULARIK INC. (US) | 2001-04-19 | — | — | WO | claimed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | claimed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | claimed |
| WO-2018128828-A1 | NOVEL HEPCIDIN MIMETICS AND USES THEREOF | BAYER HEALTHCARE LLC (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2014041559-A2 | PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-03-20 | — | — | WO | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| WO-2001027138-A2 | MODULATORS OF SREBP PROCESSING | TULARIK INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000075172-A2 | FACTOR VIIa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-14 | — | — | WO | disclosed |
| EP-1059302-A1 | Factor VIIa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | FAP, CTSC, DPP4 | PRSS1 16/4885ITGB3 3568/4885ITGA2B 3720/4885 |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | PRSS1 83/4885ITGB3 1459/4885ITGA2B 795/4885 |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | VIP, NGLY1, FURIN | PRSS1 278/4885ITGB3 2456/4885ITGA2B 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.